CrossClinic OCT Review
A clinician-side review tool that normalizes OCT scans from different devices and clinics, surfacing reliable retinal-layer thickness trends for neurodegenerative disease monitoring in MS, Alzheimer's, and Parkinson's patients.
neurologists and neuro-ophthalmologists tracking patients at risk of or living with neurodegenerative disease
- Device-agnostic normalization that aligns scans from Heidelberg, Zeiss, Optovue, and Topcon into a common anatomical reference
- Longitudinal thickness charts per retinal layer with flagged deviations from the patient's own baseline, not population averages
- Topology-aware review that flags anatomically implausible segmentations a human eye often misses
- One-page clinician report exportable to the EHR with biomarker trend, deviation flag, and a confidence note
OCT use for neurodegenerative biomarkers is growing fast, but cross-clinic and cross-device variability undermines the longitudinal tracking clinicians actually need; the underlying research now demonstrates the spatial normalization required to make this reliable at scale.
Multiple peer-reviewed sources and Practical Neurology state OCT is increasingly incorporated into routine clinical care for MS, and the global neurological biomarkers market is projected to surpass $34B by 2035, signaling strong upstream demand for longitudinal neuro-monitoring tools.MS Minute: Retinal Optical Coherence Tomography for MS ↗Neurological Biomarkers Market Size to Surpass USD 34.02 Bn by 2035 ↗
Voxeleron Orion already offers vendor-neutral, 8-layer, cross-device OCT segmentation but explicitly markets itself as a research tool, not for clinical use; RetInSight is MDR-certified but ophthalmology-focused — leaving genuine whitespace for a clinical-grade, neurology-fronted longitudinal tracker.Orion: Advanced OCT Analysis Software | Voxeleron ↗AI-Powered Analysis of OCT Images for Retinal Disease | RetInSight ↗
Reading centers and pharma sponsors clearly pay premium prices for vendor-neutral OCT analysis (Orion's pharma trial customers and iNebula eCRF platform validate this), but neurologist-driven clinical adoption will require MDR/FDA clearance and longer sales cycles into hospital neurology budgets, tempering near-term monetization.Orion: Advanced OCT Analysis Software | Voxeleron ↗Neurological Biomarkers Market Size Report, 2026-2033 ↗
Aging populations, rising MS/AD/PD prevalence, and the structural shift toward imaging biomarkers for neurodegenerative disease give this a multi-decade runway with no near-term saturation risk.
The cited arXiv work demonstrates spatial normalization is achievable, but clinical-grade deployment requires FDA 510(k)/CE-MDR clearance, multi-vendor validation datasets, and EHR/PACS integration — non-trivial regulatory and data-engineering lift.